Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary Immunodeficiency

Business Wire September 12, 2014

Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation

PR Newswire September 3, 2014

Halozyme Reports Second Quarter 2014 Financial Results

PR Newswire August 11, 2014

Halozyme to Host second Quarter 2014 Financial Results Conference Call

PR Newswire August 4, 2014

FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency

Business Wire July 31, 2014

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer

PR Newswire July 22, 2014

Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme

PR Newswire June 25, 2014

Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference

PR Newswire June 17, 2014

Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions

PR Newswire June 15, 2014

Is Small-Cap Biotech Halozyme Therapeutics Gaining Momentum?

Equities.com June 12, 2014

Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer

PR Newswire June 4, 2014

Halozyme Therapeutics To Present At The Jefferies 2014 Global Health Care Conference

PR Newswire May 29, 2014

Halozyme Therapeutics To Present At The UBS 2014 Global Health Care Conference

PR Newswire May 14, 2014

Halozyme Reports First Quarter 2014 Financial Results

PR Newswire May 12, 2014

Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference

PR Newswire May 7, 2014

Halozyme to Host first Quarter 2014 Financial Results Conference Call

PR Newswire May 5, 2014

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Halozyme Therapeutics, Inc.

Business Wire April 21, 2014

Robbins Arroyo LLP Is Investigating the Officers and Directors of Halozyme Therapeutics, Inc. on Behalf of Shareholders

PR Newswire April 17, 2014

Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme

PR Newswire April 9, 2014

Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting

PR Newswire April 8, 2014